Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Utility of BRAF V600E

The Utility of BRAF V600E RESEARCH ARTICLE V600E The Utility of BRAF Mutation-specific Antibody for Colon Cancers With Microsatellite Instability Stephanie Nolan, MD,* Thomas Arnason, MD, FRCPC,* Arik Drucker, MD, FRCPC,w and Weei-Yuarn Huang, MD, PhD, FRCPC* Key Words: BRAF, V600E, colon cancer, microsatellite in- Abstract: This study’s objective was to assess the performance of stability, Lynch syndrome V600E immunohistochemical staining with the BRAF mutation- (Appl Immunohistochem Mol Morphol 2014;22:e8–e13) specific antibody (clone VE1) in tissue from colon cancers, in- cluding those with a high degree of microsatellite instability (MSI-H). VE1 was applied to tissue microarrays of 152 colon cancers with known MSI status. Results of im- olorectal cancers (CRC) related to Lynch syndrome munohistochemical analyses were scored as negative, positive, Crepresent 2% to 3% of all CRC. Their hallmark or equivocal. The results of VE1 immunohistochemical analysis association is a high degree of microsatellite instability V600E were compared with BRAF mutation analysis by PCR. (MSI-H) resulting from germline mutations in one of the Fifteen of the 152 cases (10%) were positive with VE1 im- mismatch repair (MMR) genes (MLH1, MSH2, MSH6, munohistochemical analysis, 8 were equivocal, and 129 were and PMS2). The remaining 10% to 15% of MSI-H CRC negative. There was a http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Loading next page...
 
/lp/wolters-kluwer-health/the-utility-of-braf-v600e-tURB20Ot3x
Copyright
Copyright © 2013 by Lippincott Williams & Wilkins
ISSN
1541-2016
DOI
10.1097/PAI.0000000000000026
pmid
24805134
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE V600E The Utility of BRAF Mutation-specific Antibody for Colon Cancers With Microsatellite Instability Stephanie Nolan, MD,* Thomas Arnason, MD, FRCPC,* Arik Drucker, MD, FRCPC,w and Weei-Yuarn Huang, MD, PhD, FRCPC* Key Words: BRAF, V600E, colon cancer, microsatellite in- Abstract: This study’s objective was to assess the performance of stability, Lynch syndrome V600E immunohistochemical staining with the BRAF mutation- (Appl Immunohistochem Mol Morphol 2014;22:e8–e13) specific antibody (clone VE1) in tissue from colon cancers, in- cluding those with a high degree of microsatellite instability (MSI-H). VE1 was applied to tissue microarrays of 152 colon cancers with known MSI status. Results of im- olorectal cancers (CRC) related to Lynch syndrome munohistochemical analyses were scored as negative, positive, Crepresent 2% to 3% of all CRC. Their hallmark or equivocal. The results of VE1 immunohistochemical analysis association is a high degree of microsatellite instability V600E were compared with BRAF mutation analysis by PCR. (MSI-H) resulting from germline mutations in one of the Fifteen of the 152 cases (10%) were positive with VE1 im- mismatch repair (MMR) genes (MLH1, MSH2, MSH6, munohistochemical analysis, 8 were equivocal, and 129 were and PMS2). The remaining 10% to 15% of MSI-H CRC negative. There was a

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: May 1, 2014

There are no references for this article.